Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results August 12, 2026 Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026 August 5, 2026 Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results May 13, 2026 Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026 May 6, 2026 Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results March 18, 2026 Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 March 11, 2026 Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) March 9, 2026 Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU January 30, 2026 Protalix BioTherapeutics Letter to Stockholders January 5, 2026
Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026 August 5, 2026
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026 May 6, 2026
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 March 11, 2026
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) March 9, 2026
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU January 30, 2026